Catalog No.: PC-38561Not For Human Use, Lab Use Only.
ATI-2173 is a novel liver-targeted prodrug of clevudine, ATI-2173 is a selective inhibitor of HBV with EC50 of 1.31 nM in primary human hepatocytes with minimal to no toxicity.
ATI-2173 is a novel liver-targeted prodrug of clevudine, ATI-2173 is a selective inhibitor of HBV with EC50 of 1.31 nM in primary human hepatocytes with minimal to no toxicity.
ATI-2173 is converted to the active 5′-triphosphate in hepatocytes.
ATI-2173 showed similar activity across HBV genotypes A, B, C, D, E, F, G, and H (EC50 of 212 nM to 718 nM) in HepG2 assays.
ATI-2173 activity was decreased by viral polymerase mutations associated with entecavir, lamivudine, and adefovir resistance, but not capsid inhibitor resistance mutations.
ATI-2173 demonstrated 82% hepatic extraction, no food effect, and greatly reduced peripheral exposure of clevudine compared with equimolar oral dosing of clevudine.
